1. Home
  2. BLNK vs STTK Comparison

BLNK vs STTK Comparison

Compare BLNK & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$1.20

Market Cap

129.3M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.10

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
STTK
Founded
2009
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.3M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BLNK
STTK
Price
$1.20
$3.10
Analyst Decision
Buy
Buy
Analyst Count
7
5
Target Price
$2.13
$4.00
AVG Volume (30 Days)
2.3M
224.7K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,631,000.00
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.69
52 Week High
$2.65
$3.12

Technical Indicators

Market Signals
Indicator
BLNK
STTK
Relative Strength Index (RSI) 37.12 79.66
Support Level $1.24 $1.93
Resistance Level $1.43 $2.18
Average True Range (ATR) 0.10 0.20
MACD 0.01 0.12
Stochastic Oscillator 6.90 98.42

Price Performance

Historical Comparison
BLNK
STTK

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: